Viking Therapeutics, Inc. (VKTX)
34.01
+0.81
(+2.44%)
USD |
NASDAQ |
Mar 26, 15:07
Viking Therapeutics Cash from Investing (Quarterly) : 75.61M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly & Co. | -2.802B |
| Amgen, Inc. | -693.00M |
| Pfizer Inc. | -6.146B |
| Hims & Hers Health, Inc. | -83.68M |
| Altimmune, Inc. | -79.16M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -85.29M |
| Cash from Financing (Quarterly) | 75.10M |
| Free Cash Flow | -278.68M |
| Free Cash Flow Per Share (Quarterly) | -0.7481 |
| Free Cash Flow to Equity (Quarterly) | -84.67M |
| Free Cash Flow to Firm (Quarterly) | -85.29M |
| Free Cash Flow Yield | -7.28% |